Astria Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.
Astria Therapeutics stock last closed at $6.37, up 0.95% from the previous day, and has decreased 59.48% in one year. It has overperformed other stocks in the Biotechnology industry by 0.22 percentage points. Astria Therapeutics stock is currently +11.17% from its 52-week low of $5.73, and -62.31% from its 52-week high of $16.90.
As of Mar 20, 2025, there are 56.43M shares of ATXS outstanding. The market cap of ATXS is $359.49M. In the last 24 hours, 184,328 ATXS shares were traded.
You will need a brokerage account to access the NASDAQ market and buy ATXS shares.
Based on our research, eToro is the best brokerage. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected the right brokerage, it's time to fill out some personal information so you can buy ATXS today.
Now that you've finished signing up on our top ranked stock market app, you need to deposit funds:
Watch this video walkthrough for more details depositing money into your investment account.
After you have selected the best place to buy Astria Therapeutics stock, it's critical to research their stock before you buy, so you actually understand the risk and opportunity.
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis quickly.
You can view all of the due diligence checks on ATXS's stock page.
You can use many financial metrics, analyses, models, and charts to gauge ATXS's true value.
Using relative valuations measures:
You can access additional valuation research on ATXS's stock here.
Out of 4 sell side analysts who give ratings on ATXS, the consensus analyst rating on Astria Therapeutics is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Astria Therapeutics stock forecast page.
Over the past 12 months, executives and large shareholders at ATXS have bought as many shares as they have sold.
Christopher Morabito, Chief Medical Officer of ATXS, was the latest ATXS insider to sell. They sold $135,940.00 worth of ATXS stock on Apr 1, 2024.
Learn more about who owns ATXS stock here.
No, Astria Therapeutics doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
You have two main types of orders:
Hit the Open Trade button and eToro will place your order.
If you need additional info about investing in stocks on eToro, watch the how to video below:
Now that you own some shares in ATXS, you'll want to stay up-to-date on your shares.
Start a watchlist to get notified of important updates regarding your ATXS stock.
To summarize, here are the 6 steps for buying Astria Therapeutics stock:
If you need a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to monitor your new investment in Astria Therapeutics, create your watchlist below.